BackgroundAdjuvant immunotherapy has significantly improved survival for patients with stage III cutaneous melanoma, yet a fraction of patients will not benefit from immune checkpoint inhibitors (ICI). The tumor microenvironment plays a pivotal role in generating durable responses to ICI. By analyzing the cellular composition of tumor-associated subsets, key immune components essential for promoting an anti-tumor environment can be pinpointed. This…
CD38hiCD19dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade
bioRxiv Cancer Biology | | Ailte, I., Chauhan, S. K., Prasmickaite, L., Bassarova, A. V., Poissonnier, A., Feenstra, M., Nyakas, M., Johannessen, B., Ryder, T., Hermann, R., Frich, L., Holth, A., Inderberg, E. M., Jespersen, H., Florenes, V. A., Kyte, J. A., Maelandsmo, G. M., Egeland, E. V.
Topics: skin-cancer, immunotherapy, new-technology